Drug repurposing to identify potential FDA-approved drugs targeting three main angiogenesis receptors through a deep

Mohammadreza Torabi1, Soroush Sardari2, Alejandro Rodríguez-Martínez3

  • 1Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Molecular Diversity
|May 26, 2025
PubMed

Insights

This study identified potential multi-target inhibitors for angiogenesis by screening FDA-approved drugs against vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR). The findings offer new therapeutic strategies for cancer treatment.

Area of Science:

  • Pharmaceutical Sciences
  • Computational Drug Discovery
  • Oncology

Background:

  • Tumor growth relies on angiogenesis, the formation of new blood vessels.
  • Targeting key receptors like VEGFR, FGFR, and EGFR is crucial for inhibiting angiogenesis.
  • Developing multi-target inhibitors can enhance efficacy and reduce side effects compared to single-target drugs.

Purpose of the Study:

  • To develop a computational methodology for discovering multi-target inhibitors of angiogenesis.
  • To screen a library of over 2000 FDA-approved drugs for potential angiogenesis inhibitors.
  • To identify novel drug candidates targeting VEGFR, FGFR, and EGFR simultaneously.

Main Methods:

  • An ensemble approach combining classification and regression models was employed.
  • Deep autoencoder classification models were used for initial screening.
  • High-throughput virtual screening integrated ten regression models to assess drug efficacy and safety.

Main Results:

  • Eleven diverse molecular scaffolds and eight FDA-approved drugs were identified as potential multi-target inhibitors.
  • The identified compounds show promise in inhibiting VEGFR, FGFR, and EGFR.
  • The study validated a novel computational approach for drug discovery.

Conclusions:

  • This research provides a valuable resource for developing novel anti-angiogenesis therapies.
  • Simultaneous targeting of VEGFR, FGFR, and EGFR offers a promising strategy to overcome drug resistance.
  • The identified drugs and scaffolds represent potential lead compounds for cancer drug development.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K